GENELUX CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
GENELUX CORPORATION (GNLX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 426.17 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Shares Granted or Issued, Share-Based Payment Arrangement › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-13
- GENELUX CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 138.01K shares, a 452.06% increase year-over-year.
- GENELUX CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 288.15K shares, a 4.78% increase year-over-year.
- GENELUX CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 11.60K shares, a 98.19% decline year-over-year.
- GENELUX CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 1.49M shares, a 640.12% increase year-over-year.
- GENELUX CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 1.81M shares, a 106.87% increase from fiscal 2024.
- GENELUX CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 872.86K shares, a 24.14% decline from fiscal 2023.
- GENELUX CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 1.15M shares, a 364.39% increase from fiscal 2022.
- GENELUX CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 247.78K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 138.01K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 426.17K shares 10-Q · filed 2026-08-13 | 437.77K shares derived: sum of 3 quarters · filed 2026-08-13 | 1.93M shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 288.15K shares 10-Q · filed 2026-05-07 | 299.75K shares derived: sum of 2 quarters · filed 2026-05-07 | 1.79M shares derived: sum of 3 quarters · filed 2026-05-07 | 1.82M shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 11.60K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 1.51M shares derived: sum of 2 quarters · filed 2026-03-19 | 1.53M shares derived: sum of 3 quarters · filed 2026-03-19 | 1.81M shares 10-K · filed 2026-03-19 |
| 2025-09-30 | 1.49M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 1.52M shares derived: sum of 2 quarters · filed 2025-11-05 | 1.79M shares 10-Q · filed 2025-11-05 | 2.43M shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | 25.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 300.00K shares 10-Q · filed 2025-08-07 | 939.48K shares derived: sum of 3 quarters · filed 2025-08-07 | 1.14M shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 275.00K shares 10-Q · filed 2025-05-06 | 914.48K shares derived: sum of 2 quarters · filed 2025-05-06 | 1.12M shares derived: sum of 3 quarters · filed 2025-05-06 | |
| 2024-12-31 | 639.48K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | 841.36K shares derived: sum of 2 quarters · filed 2025-03-28 | 872.86K shares 10-K · filed 2025-03-28 | |
| 2024-09-30 | 201.88K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 233.38K shares 10-Q · filed 2024-11-14 | ||
| 2024-06-30 | 31.50K shares 10-Q · filed 2024-08-14 | |||
| 2023-12-31 | 46.75K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | 1.15M shares 10-K · filed 2025-03-28 | ||
| 2023-09-30 | 1.10M shares 10-Q · filed 2023-11-14 | |||
| 2022-12-31 | 247.78K shares 10-K · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |